(Date:5/16/2008)... Minn., May 16 /PRNewswire-USNewswire/ -- This rel...yo Clinic in conjunction with the,National Cancer ...y being presented at the American Society of Clini...may change treatment practice,in about 25 percent ...,proposed changes to the way colorectal cancers wi...
(Date:5/16/2008)...being presented at the American Society of Clinica...y change treatment practice in about 25 percent of...roposed changes to the way colorectal cancers will...ancer Institute (NCI) SEER population-based statis...inical trial data, shows that outcomes of patients...
(Date:5/16/2008)... Declaring that Primary care medicine is in a pre...nt of the American College of Physicians (ACP), to...ers and consumers to issue a call for comprehensiv...nternists and other primary care physicians. , ...care medicine in the U.S., Dr. Dale and other pane...
(Date:5/16/2008)...ave Vital Services for Frail Seniors and People Wi...ire-USNewswire/ -- Thousands of,homecare workers a...zenegger,s proposed cuts to hours of service, wage...ia,s most vulnerable workers and the,people they s...se vital,services for seniors and people with disa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2(Date:5/16/2008)...-- Results demonstrating that TYKERB and trastuzum...tension of progression-free survival (PFS), -- Co...inside and,outside of the HER2 receptor may create...ting activity of TYKERB alone despite patients,pr...b and chemotherapy, LONDON and PHILADELPHIA, May ...
(Date:5/16/2008)...l Biomarkers -- for Lung Cancer Diagnosis and, Ide...r of Unknown Primary ...Types With High Sensitivity and, Specificity and...ncer Results of microRNA Signature to Identify Ti...ding 90% and Specificity of 99%, REHOVOT, Israel ...
(Date:5/16/2008)...al Mechanism May Offer Novel Approach to Blood ...LEANS, May 16 /- Pharmacope...nd development of novel small,molecule therapeutic...ss,Dual Acting Receptor Antagonist (DARA), showed ...s in a Phase 2a study in patients with mild to,mod...
(Date:5/15/2008)...fficacy for Population Most Affected by Disease -,...wswire-FirstCall/ --,Bayer HealthCare Pharmaceutic... ONXX ) today announced that Nexavar(R) (sorafenib...by 47.3 percent (HR=0.68;,p-value=0.014) in patien...cellular carcinoma (HCC), or primary liver cancer ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6A Patients Right to Know 3A Silver Fillings are 50 25 Mercury 5017 1A Patients Right to Know 3A Silver Fillings are 50 25 Mercury 5017 2Virus Shows Some Cancer Killing Abilities 5014 1Virus Shows Some Cancer Killing Abilities 5014 2Virus Shows Some Cancer Killing Abilities 5014 3Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 1034 1Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 1034 2Vitamin D Wont Help Prevent Most Cancers 5012 1Vitamin D Wont Help Prevent Most Cancers 5012 2Vitamin D Wont Help Prevent Most Cancers 5012 3...aracterization and Broad,Neuroprotective Propertie...imental Therapeutics , Neurodegenerative Disease S...te for ALS That Targets Mitochondrial Proteins , M...aceutical,company specializing in the discovery an... announced today that a publication entitled,"Iden...
... AMADEO, one of the,first studies to compare the ...lockers in hypertensive patients with,diabetic ne...of Hypertension, Milan. The results from this stud...significantly greater extent,than losartan.(1) ...ess, Foothills Hospital,in Calgary, Canada said "...
Other Medicine Technology:Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 2Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 3Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: